

Richtlijnen

De informatie, verwerkt tot richtlijn, gegeven op Third Injection Technique workshop in AtheNs (TITAN) held in Athens, Greece from 10-13 September, 2009, (artikel is ingediend)

Danish Nurses Organization. Evidence-based Clinical Guidelines for Injection of Insulin for Adults with Diabetes Mellitus, 2nd edition, December 2006. Available from: www.dsr.dk

Association for Diabetescare Professionals (EADV). Guideline: The Administration of Insulin with the Insulin Pen. September 2008. Available from: www.eadv.nl

Artikelen

American Diabetes Association Resource Guide 2003: Insulin Delivery. *Diabetes Forecast* 2003;56:59-76.

American Diabetes Association Position Statements: Insulin Administration. *Diabetes Care* 2004;27:S106-S107.

Ampudia-Blasco J, Girbes J, Carmena R. A case of lipoatrophy with insulin glargine. *Diabetes Care* 2005;28:2983.

Birkebaek N, Solvig J, Hansen B, Jorgensen C, Smedegaard J, Christiansen J. A 4mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults. *Diabetes Care* 2008;22: e65.

Braakter EW, Woodworth JR, Bianchi R, Cermele B, Erkelens DW, Thijssen JH, Kurtz D. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. *Diabetes Care* 1996;19:1437-1440.

Byetta Pen User Manual. Eli Lilly and Company, 2007.

Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, Fineman M. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). *Clin Ther* 2005;27:210-5.

Cefalu WT, Mathieu C, Davidson J, Freemantle N, Gough S, Canovatchel W, OPTIMIZE Coalition. Patients' perceptions of subcutaneous insulin in the OPTIMIZE study: a multicenter follow-up study. *Diabetes Technol Ther* 2008;10:25-38.

Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. *BMJ* 2003;327:383-384.

Davidson M. No need for the needle (at first). *Diabetes Care* 2008;31:2070-2071.

Davis SN, Renda SM. Psychological insulin resistance: overcoming barriers to starting insulin therapy. *Diabetes Educ* 2006;32:146S-152S.

Frid A. Fat thickness and insulin administration, what do we know? *Infusystems International* 2006;5:17-19.

Guerci B, Sauvanet JP. Subcutaneous insulin: pharmacokinetic variability and glycemic variability. *Diabetes Metab* 2005;31:4S7-4S24.

Heinemann L, Hompesch M, Kapitza C, Harvey NG, Ginsberg BH, Pettis RJ. Intra-dermal insulin lispro application with a new microneedle delivery system led to a substantially more rapid insulin absorption than subcutaneous injection. *Diabetologia* 2006;49:755, abstract 1014.

Heinemann L. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects. *Diabet Med* 1998;15:747-51.

Hofman, Paul. Getting to the Point: Injection Techniques and Needle Lengths. Presentation, *Diabetes*

Technology Society, Ninth Annual Meeting, November 5-7, 2009, San Francisco, California.

Johansson UB. Impaired absorption of insulin aspart from lipohypertrophic injection sites. *Diabetes Care* 2005;28:2025-7.

Karges B, Boehm BO, Karges W. Early hypoglycaemia after accidental intramuscular injection of insulin glargine. *Diabetic Medicine* 2005;22:1444-45.

Kreugel G, Keers JC, Jongbloed A, Verweij-Gjaltema AH, Wolffenbuttel BHR. The influence of needle length on glycemic control and patient preference in obese diabetic patients. *Diabetes* 2009;58:A117.

Kreugel G, Beijer HJM, Kerstens MN, ter Maaten JC, Sluiter WJ, Boot BS. Influence of needle size for SC insulin administration on metabolic control and patient acceptance. *European Diabetes Nursing* 2007;4:1-5.

Laurent A, Mistretta F, Bottiglioli D, Dahel K, Goujon C, Nicolas JF, Hennino A, Laurent PE. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. *Vaccine* 2007;25:6423-30.

Martinez L, Consoli SM, Monnier L, Simon D, Wong O, Yomtov B, Guéron B, Benmedjahed K, Guillemin I, Arnould B. Studying the Hurdles of Insulin Prescription (SHIP): development, scoring and initial validation of a new self-administered questionnaire. *Health Qual Life Outcomes* 2007;5:53.

Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR. Insulin aspart (B28 aspinsulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. *Diabetes Care* 1999;22:1501-6.

Nielsen BB, Musaeus L, Gæde P, Steno Diabetes Center, Copenhagen, Denmark. Attention to injection technique is associated with a lower frequency of lipohypertrophy in insulin treated type 2 diabetic patients. Abstract *EASD*, Barcelona, Spain, 1998.

Overland J, Molyneaux L, Tewari S., et al. Lipohypertrophy : Does it matter in daily life? A study using a continuous glucose monitoring system. *Diabetes, Obes Metab* 2009;11:460-3.

Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. *Diabetes Care* 2000;23:813-9.

Polonsky WH, Jackson R. What's so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. *Clinical Diabetes* 2004;22:147-150.

Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. *Diabetes Care* 2005;28:2543-5.

Rave K, Heise T, Weyer C, Herrnberger J, Bender R, Hirschberger S,

Saez-de Ibarra L, Gallego F. Factors related to lipohypertrophy in insulin-treated diabetic patients; role of educational intervention. *Practical Diabetes International* 1998;15:9-11.

Schwartz S, Hassman D, Shelmet J, Sievers R, Weinstein R, Liang J, Lyness W. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6mm needle versus a 29 gauge x 12.7mm needle in obese patients with diabetes mellitus. *Clin Ther.* 2004;26:1663-78.

Seyoum B, Abdulkadir J. Systematic inspection of insulin injection sites for local complications related to incorrect injection technique. *Trop Doct* 1996;26:159-161.

Solvig J, Christiansen JS, Hansen B, Lytzen L. Localisation of potential insulin deposition in normal weight and obese patients with diabetes using Novofine 6 mm and Novofine 12 mm needles. Abstract *FEND*, Jerusalem, Israel, 2000.

Strauss K, Hannet I, McGonigle J, Parkes JL, Ginsberg B, Jamal R, Frid A. Ultra-short (5mm) insulin needles: trial results and clinical recommendations. *Practical Diabetes* 1999;16:218-222.

Strauss K, De Gols H, Hannel I, Partanen TM, Frid A. A pan-European epidemiologic study of insulin injection technique in patients with diabetes. *Pract Diab Int* 2002;19:71-76.

Strauss K, De Gols H, Letondeur C, Matyjaszczyk M, Frid A. The second injection technique event (SITE), May 2000, Barcelona, Spain. *Pract Diab Int* 2002;19:17-21.

Van Doorn LG, Alberda A, Lytzen L. Insulin leakage and pain perception with NovoFine 6 mm and NovoFine 12 mm needle lengths in patients with type 1 or type 2 diabetes. *Diabetic Medicine* 1998;1:S50.

Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. *Diabetes Res Clin Pract* 2007;77:231-6.

Young RJ, Hannan WJ, Frier BM, Steel JM, et al. Diabetic lipohypertrophy delays insulin absorption. *Diabetes Care* 1984;7:479-480.

Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. *Diabetes Res Clin Pract* 1999;46:239-46.